Call us today 855-494-4867
Call us today 855-494-4867
KEY FINDINGS FROM THE LARGEST EVER NIMH DEPRESSION TREATMENT STUDY
•The NIMH-funded Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study was conducted to determine the effectiveness of different treatments for people with major depression who have not responded to initial treatment with an antidepressant.1
• The outcome measure was a “remission” of depressive symptoms—becoming symptom-free. This outcome was selected because people who reach this goal generally function better socially and at work, and have a better chance of staying well than do people who only achieve a response but not a remission. 2
• With 4,041 adult outpatients from 41 clinical sites around the country, over a 7 year period, STAR*D is the largest and longest study ever conducted to evaluate depression treatment.3
• Significantly, STAR*D found that the likelihood of achieving remission on the 3rd or 4th medication is <25%. 4
Transcranial Magnetic Stimulation (TMS) is cleared by the U.S. Food and Drug Administration (FDA) for major depressive disorder (MDD) in patients who have not responded to 1 adequate antidepressant trial in the current episode. 6
(1) https://www.nimh.nih.gov/funding/clinical-research/practical/stard/ (2) https://www.nimh.nih.gov/funding/clinical-research/practical/stard/allmedicationlevels (3) Ibid. (4) Ibid. (5) HAMD 17, also known as the Hamilton Depression Rating Scale (HDRS), is a widely used 17 question clinician-administered depression assessment scale (6) O’Reardon et al., 2012 Apr, PMID: 22579164
Greenbrook supports an accessible internet. If you have any questions about our accessibility features, please contact us at
(855) 494-4867 and/or info@greenbrooktms.com.
All Rights Reserved | Greenbrook TMS NeuroHealth Centers.